Adding ribociclib, a CDK*4/6 inhibitor, to NSAI** and goserelin improves progression-free survival (PFS) in premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC), according to the MONALEESA-7*** study presented at ESMO Asia 2018.
Incorporating polygenic risk scores based on 18 SNPs (single nucleotide polymorphisms) into risk stratification for breast cancer will improve screening results, says an expert.
Making genetic testing mainstream, allows more patients to be tested, identifies more carriers and enables appropriate stratification of treatment and outcomes, says an expert.
Hereditary breast and ovarian cancer (HBOC) syndrome, which is primarily caused by BRCA1 and BRCA2 mutations, make up 8 to 10 percent of all breast cancers, says a senior consultant.
Final analysis of results from the PALOMA-3 study showed improvement in overall survival (OS) with addition of cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib to fulvestrant in hormone receptor−positive, HER2-negative advanced breast cancer that has relapsed or progressed on hormonal therapy.